The authors regret that “Bharat Biotech Covaxin” was misreported as “Novavax-Serum Institute Covovax NVX-CoV2373”. The locations of the error in the manuscript are:
-
•
Page 214, paragraph 1, sentence 4
-
•
Page 214, Section 3.4.1. SARS-CoV-2 vaccination for the prevention of long COVID, paragraph 1, sentence 2
-
•
Page 214, section 3.4.1. SARS-CoV-2 vaccination for the prevention of long COVID, paragraph 5, sentence 1
-
•
Table 1, Page 216, Row: “Arjun et al, 2022*”, Column: “Vaccinated (Treatment) Group”, last bullet point
At the foregoing locations in the text, “Novavax-Serum Institute Covovax NVX-CoV2373” should read “Bharat Biotech Covaxin”. Notably, one of the component studies reported that two doses of the Bharat Biotech Covaxin vaccine were associated with an increased odds of long COVID (aOR 2.32, 95% CI 1.17–4.58, p = 0.01, N = 487)1; this finding was not reported in association with the Novavax-Serum Institute Covovax NVX-CoV2373 vaccine. The authors would like to apologise for any inconvenience caused.
1. Arjun MC, Singh AK, Pal D, et al. Prevalence, characteristics, and predictors of Long COVID among diagnosed cases of COVID-19. bioRxiv. Published online January 8, 2022. https://doi.org/10.1101/2022.01.04.21268536.